Abeta42

Abeta42

One of the 2 cleavage products of amyloid precursor protein, overproduction of which is linked to neurotoxicity in patients with Alzhemier’s disease.
References in periodicals archive ?
They discovered that increases in levels of their newly identified peptide (APL1beta28) reflected increased production of Abeta42 in the brain.
In addition, Professor Bush referenced studies he and colleagues performed on 15-month old transgenic Alzheimer's mice treated with 30 mg/kg PBT2, which showed the drug reduced soluble Abeta40 and Abeta42 levels by 60 percent within 24 hours of oral PBT2 administration.
These forward-looking statements include: The Company's belief that Flurizan is the first well-tolerated drug that inhibits the production of Abeta42; the role of Abeta42 in Alzheimer's disease; the ability of Flurizan to inhibit the production of Abeta42, and its ability to treat patients with Alzheimer's disease.
Flurizan has been shown to be effective in lowering levels of Abeta42 in cellular assays and animal models.
Nicolas Sergeant from INSERM in France entitled "Amino-truncated A-beta 42 species as early diagnostic and etiological biomarkers of Alzheimer's disease" described using a SELDI immunoassay to evaluate the presence of N-terminally truncated Abeta42 peptides in patient cerebrospinal fluid (CSF).
The trial is designed to demonstrate the efficacy of Flurizan in the slowing as well as the potential reversal of cognitive decline in Alzheimer's disease patients, by lowering the toxic peptide Abeta42, the primary culprit in Alzheimer's disease and a major component of senile plaques in the brain.
The finding strengthens the leading hypothesis among Alzheimer's disease researchers that lowering the toxic peptide Abeta42 may be an effective treatment for patients suffering from Alzheimer's disease.
The study was designed to determine whether a reduction in the toxic Abeta42 peptide leads to improvement in memory and spatial learning in a mouse model of human Alzheimer's disease.
The Abeta42 peptide was further recognized by the scientific community as an important drug target in the effort to create drugs that may halt the cognitive decline of Alzheimer's disease.
Abeta42 is thought to activate microglia and astrocytes -- brain cells that, when stimulated, release a variety of inflammatory molecules.
announced today that its Alzheimer's disease candidate drug, MPC-7869 (R-flurbiprofen) reduces levels of Abeta42 more effectively than any other compound tested, according to a new study.
Myriad has received worldwide exclusive therapeutic rights to the drug candidates and to further drug discoveries that result from collaboration on compounds that lower the beta amyloid peptide, Abeta42.